Prevalence of kidney injury in patients taking tenofovir based antiretroviral therapy at a primary health care clinic, in East Rand,Gauteng Province

References

• Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat. 2011;11.DOI: 10.1155/2011/562790
   Google Scholar
• Elias A, Ijeoma O, Edikpo NJ, et al. Evaluation of cohorts and clinical studies-part one. Pharmacol Pharm. 2013;4:651–662.
   Google Scholar
• Scarpino M, Pinzone MR, Di Rosay M, et al. Kidney disease in HIV-infected patients. Eur Rev Med Pharmacol Sci. 2013;17:2660–2667.
   PubMed Web of Science ®Google Scholar
• Baxi SM, Scherzer R, Greenblatt RM, et al. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. AIDS. 2016;30(4):609–618.
   PubMed Web of Science ®Google Scholar
• Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011. DOI: 10.1155/2011/354908
   PubMedGoogle Scholar
• National Department of Health Republic of South Africa. South African antiretroviral treatment clinical guidelines for the management of HIV in adults, pregnancy, adolescents, children, infants and neonates. Published May 2019.
   Google Scholar
• Hall AM. Update on tenofovir toxicity in the kidney. Pediatric Nephrol. 2013;28:1011–1023.
   PubMed Web of Science ®Google Scholar
• The standard treatment guidelines and essential medicines list for South Africa. © Department of Health, Republic of South Africa December 2014.
   Google Scholar
• World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommended for a public health approach 2nd edition. 2016.
   Google Scholar
• Jose S, Hamzan L, Campbell LJ, et al. Incomplete reversibility of estimated glomerular filtration rate decline following disoproxil fumarate exposure. J Infect Dis. 2014;210(3):363–373.
   PubMed Web of Science ®Google Scholar
• Venter W, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018;19(1):817.
   PubMedGoogle Scholar
• Chadwick DR, Sarfo FS, Kirk ESM, et al. Tenofovir is associated with increased proteinuria and asymptomatic renal tubular dysfunction in Ghana. BMC Nephrol. 2015;16 (1)(195).
   Google Scholar
• Patel KK, Patel AK, Ranjan RR, et al. Tenofovir-associated renal dysfunction in clinical practice: observational cohort from western India. Indian J Sex Transm Dis AIDS. 2010;31(1):30–34.
   PubMedGoogle Scholar
• Kamkuemah M, Kaplan R, Bekker LG, et al. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a primary healthcare setting in South Africa. Trop Med Int Health. 2014;20(4):518–526.
   PubMed Web of Science ®Google Scholar
• Li X, Zhuang S. Acute kidney injury in HIV infection. J Trop Diseases. 2013;1:101.
   PubMedGoogle Scholar
• Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological and mitochondrial abnormalities. Kidney Int. 2010;78(11):1171–1177.
   PubMed Web of Science ®Google Scholar
• Bonjoch A, Echeverria P, Perez-Alvarez N, et al. High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Elsevier. 2012;96(1):65–69.
   Google Scholar
• Yoshino M, Yagura H, Kushida H, et al. Assessing recovery of renal function after disoproxil fumarate discontinuation. J Infect Chemother. 2012;18(2):169–174.
   PubMed Web of Science ®Google Scholar
• Wever K, van Agtmael M, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010;55(1):78–81.
   PubMed Web of Science ®Google Scholar
• De Boer Y, De Lannoy R, Orhan R, et al. Reversibility of tenofovir nephrotoxicity in HIV-positive patients: a systemic review. Erasmus J Med. 2015;5(1) p.38.
   Google Scholar
• Sandre A, Mushi N, Dhande S, et al. Tenofovir-induced acute kidney injury in HIV-infected patients in western India: a resource limited setting perspective. Int AIDs Soc. 2012;15:18308.
   Google Scholar
• Gupta A, Wood R, Kaplan R, et al. Prevalent and Incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS ONE. 2013;8(2):e55824.
   PubMed Web of Science ®Google Scholar
• Levin A, Stevens PE. Summary of KDIGO 2012 guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1): 49–6.
   Web of Science ®Google Scholar
• Statistics South Africa: mid-year population estimates. 2018. [cited 2020 Apr 20]. Available from: www.statsa.gov.za
   Google Scholar
• Shisana O, Rice K, Zungu N, et al. Gender and poverty in South Africa in the era of HIV/AIDs: A quantitative study. J Women’s Health. 2010;19(1). DOI:10.1089/jwh.2008.1200.
   PubMed Web of Science ®Google Scholar
• Franey C, Knott D, Barnighausen T, et al. Renal impairment in rural African antiretroviral programme. BMC Infect Dis. 2009;9:143.
   PubMed Web of Science ®Google Scholar
• Ojeh BV, Abah IO, Ugoagwu P, et al. Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients. Germs. 2018;8(2):67–76.
   PubMedGoogle Scholar
• Vance DE, Mugavero M, Raper JL, et al. Aging with HIV: A cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care. 2011;22(1):17–19.
   PubMed Web of Science ®Google Scholar
• Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–875.
   PubMed Web of Science ®Google Scholar
• Ibrahim F, Naftalin C, Cheserem E, et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. Clin Sci. 2010;24(14):2239–2244.
   Google Scholar
• Kyaw NT, Harries CP, Antierens A, et al. Low incidence of renal dysfunction among HIV-infected patients on a tenofovir based first line antiretroviral treatment regimen in Myanmar. Plos One. 2015;10(8):e0135188.
   PubMed Web of Science ®Google Scholar
• Boswell MT, Rossouw TM. Approach to acute kidney injury in HIV-infected patients in South Africa. South Afr J HIV Med. 2017;18(1):714.
   PubMed Web of Science ®Google Scholar
• Choto M, Chitura M. Factors associated with antiretroviral treatment default at citimed hospital, Zimbabwe. Afr Educat Res J. 2017;5(4): 215–220. ISSN: 2354-2160.
   Google Scholar
• Amond A, Motala A, Levitt N, et al. The 2012 SEMDSA guideline for the management of type 2 diabetes. J Endocrinol Metabolism Diabetes South Afr. 2012;17(1):S1–S94.
   Google Scholar
• Supran HS, Gokhale S, Sathian B, et al. Hepatitis B virus (HBV and Hepatitis C virus (HCV) co-infection among HIV individuals at Tertiary care hospital in western Nepal. Nepal J Epidemiol. 2015;5(2):488–493.
   PubMed Web of Science ®Google Scholar
• Rouet F, Deleplancque I, Mboumba BB, et al. Usefulness of a fourth generation ELISA assay for the reliable identification of HCV infection in HIV positive adults from Gabon (Central Africa). Plos One. 2015;10(1):e0116975.
   PubMed Web of Science ®Google Scholar
• Matthews C, Beloukas A, Malik A, et al. Prevalence and characteristics of hepatitis B virus (HBV) co-infection among HIV positive women in South Africa and Botswana. Plos One. 2015;10(7):e0134037.
   PubMed Web of Science ®Google Scholar
• Nolin TD, Himmelfarb J. Mechanisms of drug-induced nephrotoxicity. In: Uetrech J, editor. adverse drug reactions. Handbook of experimental pharmacology. Vol. 196, 2010:111-130. Springer, Berlin,Heildelberg.
   Google Scholar
• Zitha AN, Schellack N, Gous AGS. Renal monitoring of patients treated with tenofovir at Odi hospital in Gauteng province, South Africa. Afr J Phys Health Sci (AJPHES). 2017;1:128–145.
   Google Scholar
• Chua AC, Llorin RM, Lai K, et al. Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort. AIDS Res Ther. 2012;9(1).:19
   PubMed Web of Science ®Google Scholar
• De Waal R, Cohen K, Fox M, et al. Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: A retrospective cohort study. J Int AIDS Soc. 2017;20:21317.
   PubMed Web of Science ®Google Scholar
• De Beaudrap P, Diallo MB, Landman R, et al. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retroviruses. 2010;26(11). DOI:10.1089/aid.2009.0261.
   PubMed Web of Science ®Google Scholar
• Munikrishnappa D. Chapter 6: limitations of various formulae and other ways of assessing GFR in the elderly: is there a role for cystatin C.. Am Soc Nephrol. 2009.
   Google Scholar